RAGE

RAGE Molekülinformation

Englischer Name	Advanced glycosylation end product-specific receptor	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3	Target-Alias	Receptor for advanced glycosylation end products，AGER，Advanced Glycosylation End-Product Specific Receptor，RAGE，Receptor For Advanced Glycation End-Products Variant 20，Receptor For Advanced Glycation End-Products，RAGE Isoform NtRAGE-Delta，RAGE Isoform SRAGE-Delta，SCARJ1，Receptor for Advanced Glycation End Products，Advanced glycosylation end product-specific receptor
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

Englischer Name	Advanced glycosylation end product-specific receptor
Target-Alias	Receptor for advanced glycosylation end products，AGER，Advanced Glycosylation End-Product Specific Receptor，RAGE，Receptor For Advanced Glycation End-Products Variant 20，Receptor For Advanced Glycation End-Products，RAGE Isoform NtRAGE-Delta，RAGE Isoform SRAGE-Delta，SCARJ1，Receptor for Advanced Glycation End Products，Advanced glycosylation end product-specific receptor
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

RAGE Produktliste

Attribut
Cell (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
- (1)
Marker
- (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
CHEK-ATP156	Human	HEK293	HEK293/Human RAGE Stable Cell Line				In den Warenkorb legen

Gesamtmenge1

RAGE Molekülhintergrund

Advanced glycosylation end product-specific receptor (AGER) is also known as RAGE, and is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. AGER is highly expressed in endothelial cells. AGER mediates interactions of advanced glycosylation end products (AGE), and also accumulates in vascular tissue in aging and at an accelerated rate in diabetes, as well as acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGER / RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes.

RAGE Molekülalias

AGER,RAGE

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Azeliragon	TTP-488; PF-4494700; PF-04494700	Phase 3 Clinical	Vtv Therapeutics	Alzheimer Disease; Brain metastases; Breast Neoplasms; Coronavirus Disease 2019 (COVID-19); Diabetic Nephropathies; Glioblastoma; Glioma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms	Details
TRC-4186	TX-41XX; TRC-4186	Phase 2 Clinical	Torrent Pharmaceuticals Ltd	Diabetes Complications; Heart Failure	Details
ARO-RAGE		Phase 2 Clinical	Arrowhead Pharmaceuticals Inc	Asthma	Details